Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Inebilizumab shows promise in a tough-to-treat MG subgroup. In MuSK-positive myasthenia gravis patients, inebilizumab outperformed placebo on key clinical scores during the randomized phase, with benefits extending further into an open-label period. Though the analysis is descriptive rather than statistical, the results are clinically meaningful for a subgroup known for more severe disease.
Inebilizumab shows promise in a tough-to-treat MG subgroup
MuSK-positive myasthenia gravis (MuSK+ MG) is a distinct and often more severe form of the disease — and new data suggest inebilizumab may offer real benefit for these patients. In the randomized controlled phase (RCP) of the trial, 48 MuSK+ patients were enrolled, with inebilizumab showing greater reductions in both the MG Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores compared to placebo.
Improvements continued to deepen into the open-label period (OLP), with patients who crossed over from placebo to inebilizumab also showing meaningful gains by week 52.
By the Numbers:
Why it matters: MuSK+ MG patients are often harder to treat and experience more severe symptoms. While this analysis is descriptive and not powered for statistical significance, the consistent clinical improvements across both phases suggest inebilizumab could be a meaningful option for this underserved subgroup.
